Levovanox

Vancomycin, the active ingredient in Levovanox, is a glycopeptide antibiotic presented as a sterile powder for reconstitution for intravenous or oral use. It is employed to treat severe Gram‑positive bacterial infections, including those caused by methicillin‑resistant Staphylococcus aureus (MRSA) and Clostridioides difficile‑associated colitis, in adult and pediatric patients where appropriate.

GNH USA supplies Levovanox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Levovanox (vancomycin) is indicated for serious infections caused by Gram‑positive bacteria and is used in specific clinical pathways targeting resistant organisms. - Severe Gram‑positive infections: provides bactericidal activity to eradicate pathogens such as Staphylococcus aureus and Enterococcus species. - Methicillin‑resistant Staphylococcus aureus (MRSA): treats infections resistant to beta‑lactam antibiotics, including skin, bloodstream, and pneumonia cases. - Clostridioides difficile‑associated colitis (oral formulation): restores gut flora balance by targeting toxin‑producing C. difficile bacteria.

Adverse reactions may occur with vancomycin therapy and should be monitored.

Common Side Effects: - Red man syndrome: flushing and rash often related to rapid infusion. - Nausea or vomiting: gastrointestinal discomfort during treatment. - Diarrhea: may range from mild to moderate severity. - Elevated liver enzymes: transient hepatic enzyme changes.

Serious or Rare Side Effects: - Nephrotoxicity: potential kidney function impairment requiring monitoring. - Ototoxicity: possible hearing loss or vestibular dysfunction, especially with high trough levels. - Anaphylaxis: rare severe allergic reaction with hypotension and airway compromise.

Vancomycin requires careful clinical monitoring to minimize risks. - Renal function: assess baseline and periodic creatinine clearance. - Hearing assessment: monitor for signs of ototoxicity, especially in prolonged therapy. - Infusion rate: administer over at least 60 minutes to reduce red man syndrome. - Pregnancy: use only if benefits outweigh potential risks (Category C). - Storage: Store below 25°C: keep in the original container, protect from moisture and light.

Vancomycin may interact with other agents, affecting efficacy or safety.

Major Interactions (Avoid): - Aminoglycosides: increased risk of nephrotoxicity when combined. - Loop diuretics: may potentiate renal impairment.

Moderate Interactions (Monitor Closely): - NSAIDs: can exacerbate renal dysfunction. - Neuromuscular blockers: may enhance neuromuscular blockade. - Warfarin: occasional alteration of INR, requiring closer monitoring.